Plasma-derived circALG8 and circCAMTA1 as a panel for early diagnosis of non-small cell lung cancer.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-08-01 Epub Date: 2025-08-03 DOI:10.1080/17520363.2025.2542115

Yufei Sheng, Lulu Yang, Boyang Wang, Zhiqi Hong, Jin Guo, Chengwei Zhou, Tao Li, Wentao Hu, Zhaohui Gong

{"title":"Plasma-derived circALG8 and circCAMTA1 as a panel for early diagnosis of non-small cell lung cancer.","authors":"Yufei Sheng, Lulu Yang, Boyang Wang, Zhiqi Hong, Jin Guo, Chengwei Zhou, Tao Li, Wentao Hu, Zhaohui Gong","doi":"10.1080/17520363.2025.2542115","DOIUrl":null,"url":null,"abstract":"Background: Endogenous circular RNAs (circRNAs) have been implicated in the progression of cancer. This study aims to identify and evaluate the diagnostic efficacy of the newly found circALG8 and circCAMTA1 in patients with non-small cell lung cancer (NSCLC).Methods: Differentially expressed circRNAs were identified through plasma circRNA sequencing, followed by validation in NSCLC tissues and plasma samples using RT-qPCR. The stability of circALG8 and circCAMTA1 was determined by RNase R and actinomycin D assays. Receiver operating characteristic (ROC) curve analysis was employed to evaluate the diagnostic performance of these circRNAs in comparison to traditional tumor biomarkers.Results: Both circALG8 and circCAMTA1 are significantly downregulated in tumor tissues and plasma from NSCLC patients, correlating closely with TNM staging. The two circRNAs are structurally stable circular RNA molecules, demonstrating considerable stability in plasma of NSCLC patients. The combined plasma circALG8 and circCAMTA1 hold the potential to serve as a diagnostic panel for early-stage NSCLC (AUC: 0.8987, p < 0.0001). Importantly, the combination of the plasma circRNA panel enhances the diagnostic efficacy of traditional tumor biomarkers (AUC: 0.9236, p < 0.0001) in early diagnosis of NSCLC.Conclusion: Plasma-derived circALG8 and circCAMTA1 May function as a diagnostic panel, thereby improving the diagnostic accuracy for early-stage NSCLC.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"725-736"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416200/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2542115","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Endogenous circular RNAs (circRNAs) have been implicated in the progression of cancer. This study aims to identify and evaluate the diagnostic efficacy of the newly found circALG8 and circCAMTA1 in patients with non-small cell lung cancer (NSCLC).

Methods: Differentially expressed circRNAs were identified through plasma circRNA sequencing, followed by validation in NSCLC tissues and plasma samples using RT-qPCR. The stability of circALG8 and circCAMTA1 was determined by RNase R and actinomycin D assays. Receiver operating characteristic (ROC) curve analysis was employed to evaluate the diagnostic performance of these circRNAs in comparison to traditional tumor biomarkers.

Results: Both circALG8 and circCAMTA1 are significantly downregulated in tumor tissues and plasma from NSCLC patients, correlating closely with TNM staging. The two circRNAs are structurally stable circular RNA molecules, demonstrating considerable stability in plasma of NSCLC patients. The combined plasma circALG8 and circCAMTA1 hold the potential to serve as a diagnostic panel for early-stage NSCLC (AUC: 0.8987, p < 0.0001). Importantly, the combination of the plasma circRNA panel enhances the diagnostic efficacy of traditional tumor biomarkers (AUC: 0.9236, p < 0.0001) in early diagnosis of NSCLC.

Conclusion: Plasma-derived circALG8 and circCAMTA1 May function as a diagnostic panel, thereby improving the diagnostic accuracy for early-stage NSCLC.

查看原文本刊更多论文

血浆源性circALG8和circCAMTA1作为非小细胞肺癌早期诊断的指标。

背景：内源性环状rna （circRNAs）与癌症的进展有关。本研究旨在鉴定和评价新发现的circALG8和circCAMTA1在非小细胞肺癌（NSCLC）患者中的诊断效果。方法：通过血浆circRNA测序鉴定差异表达的circRNA，然后使用RT-qPCR在NSCLC组织和血浆样本中进行验证。通过RNase R和放线菌素D检测circALG8和circCAMTA1的稳定性。与传统肿瘤生物标志物相比，采用受试者工作特征（ROC）曲线分析来评估这些环状rna的诊断性能。结果：circALG8和circCAMTA1在NSCLC患者肿瘤组织和血浆中均显著下调，且与TNM分期密切相关。这两种环状RNA是结构稳定的环状RNA分子，在NSCLC患者血浆中表现出相当大的稳定性。血浆circALG8和circCAMTA1联合检测具有作为早期非小细胞肺癌诊断面板的潜力（AUC: 0.8987, p）。结论：血浆circALG8和circCAMTA1可作为早期非小细胞肺癌的诊断面板，从而提高早期非小细胞肺癌的诊断准确性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.